Role of iron in the potentiation of anthracycline cardiotoxicity; Identification of heart cell mitochondria as a major site of iron-anthracycline interaction

Journal of Laboratory and Clinical Medicine

Volumn 127, Issue 3, 1996, Pages 272-278

  Link, Gabriela ^b   Tirosh, Regine ^b   Pinson, Arie ^b   Hershko, Chaim ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC; BETA N ACETYLHEXOSAMINIDASE; DEFERIPRONE; DEFEROXAMINE; DOXORUBICIN; IRON; IRON CHELATING AGENT; LACTATE DEHYDROGENASE; PYRIDONE DERIVATIVE;

ANIMAL; ARTICLE; CELL CULTURE; DRUG EFFECT; FEMALE; HEART; HEART MITOCHONDRION; HEART MUSCLE; METABOLISM; PATHOLOGY; PHYSIOLOGY; RAT; WISTAR RAT;

ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BETA-N-ACETYLHEXOSAMINIDASE; CELLS, CULTURED; DEFEROXAMINE; DOXORUBICIN; FEMALE; HEART; IRON; IRON CHELATING AGENTS; L-LACTATE DEHYDROGENASE; MITOCHONDRIA, HEART; MYOCARDIUM; PYRIDONES; RATS; RATS, WISTAR;

EID: 0030091567     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(96)90095-5     Document Type: Article

References (43)

1. Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med 1981;305:139-53.
2. Heishko C, Link G, Tzahor M, et al. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J LAB CLIN MED 1993;122:245-51.
3. Link G, Pinson A, Hershko C. Heart cells in culture: a model of myocardial iron overload and chelation. J LAB CLIN MED 1985; 106:147-53.
4. Iancu TC, Shiloh H, Link G, Bauminger ER, Pinson A, Hershko C. Ultrastructural pathology of iron-loaded rat myocardial cells in culture. Br J Exp Pathol 1987;68:53-65.
5. Bauminger ER, Iancu TC, Link G, Pinson A, Hershko C. Iron overload in cultured rat myocardial cells. Hyperfine Interact 1987;33:249-62.
6. Hershko C, Link G, Pinson A. Modification of iron uptake and lipid peroxidation by hypoxia, ascorbic acid, and α-tocopherol in iron-loaded rat myocardial cell cultures. J LAB CLIN MED 1987: 110:355-61.
7. Pinson A, Padieu P, Harary I. Techniques for culturing heart cells. In: Pinson AA, ed. The heart cell in culture (vol 1). Boca Raton: CRC Press Inc., 1987:7-22.
8. Hider RC, Kontoghiorghes G, Silver J. UK. Patent GB-2118176, 1982.
9. Wroblewski F, LaDue J. Lactic dehydrogenase activity in blood. Proc Soc Exp Biol Med 1955;90:210-3.
10. Aronson NN, Touster O. Isolation of rat liver plasma membrane fragments in isotonic sucrose. Methods Enzymol 1974;31:90.
11. Ames BN. Assay of inorganic phosphate, total phosphate and phosphatases. Methods Enzymol 1966;8:115-7.
12. Galjaard H. Genetic metabohc diseases. Early diagnosis and prenatal analysis. Amsterdam: Elsevier North Holland, 1980: 827.
13. Pinson A, Desgres J, Heller M. Partial and incomplete oxidation of palmitate by cultured beating cardiac cells from neonatal rats. J Biol Chem 1979;254:8331-5.
14. Mode EB. Elements of statistics. 3rd ed. Englewood Clifls, New Jersey: Prentice-Hall Inc., 1961:161-9.
15. Voest EE. Iron chelation, oxygen radicals, and anthracyclines in the treatment of cancer [Doctoral thesis, University of Utrecht]. Utrecht, The Netherlands: Kwiek BV Press, 1993:11-8.
16. Link G, Pinson A, Hershko C. Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxvpyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells. Blood 1994;83:2692-7.
17. Link G, Pinson A, Hershko C. Iron-loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. J LAB CLIN MED 1993;121:127-34.
18. Mak IT, Weglicki WB. Characterization of iron-mediated peroxidative injury in isolated hepatic lysosomes. J Clin Invest 1985;75:58-63.
19. Seymour CA, Peters TJ. Organelle pathology in primary and secondary haemochromatosis with special reference to lysosomal changes. Br J Haematol 1978:40:239-53.
20. Boucek RJ, Kunkel EM, Graham TP, Brenner D, Olson RD. Doxorubicinol, the metabolite of doxorubicin, is more cardiotoxic than doxorubicin. Pediatr Res 1987;21:187A.
21. Caroni P, Villani F, Carafole E. The cardiotoxic antibiotic doxorubicin inhibits the Na/Ca exchange of dog heart sarcolemmal vesicles. FEBS Lett 1981;130:184-6.
22. Harada H, Cusack BJ, Olson RD, et al. Taurine deficiency and doxorubicin: interaction with the cardiac sarcolcmmal calcium pump. Biochem Pharmacol 1990;39:745-51.
23. Singal PK. Ultrastructural evidence for increased sensitivity of the hypertrophied heart to adriamycin. Perspect Cardiovasc Res 1983;7:197-209.
24. Singal PK, Segstro RJ, Singh RP, Kutryk MJ. Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy. Can J Cardiol 1985;1:139-47.
25. + binding and lipid peroxidation but depresses myocardial function. Am J Physiol 1986;250:H419-25.
26. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990;4:3076-86.
27. Singal PK, Deally CMR, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 1987;19:817-28.
28. Povis G. Free radical formation by antitumor quinones. Free Radic Biol Med 1989;6:63-101.
29. Goormaghtigh E., Ruysschaert JM. Anthracycline gtycosidemembrane interactions. Biochim Biophys Acta 1984;779:271-88.
30. Mailler K, Petering DH. Inhibition of the oxidative phosphorylation in tumor cells and mitochondria by daunomycin and adriamycin. Biochem Phannacol 1976;25:2085-9.
31. Parkes JG, Thompson W. The composition of phospholipids in outer and inner mitochondrial membranes from guinea pig liver. Biochim Biophys Acta 1970;196:162-9.
32. Fry M, Green DE. Cardiolipin requirement by cytochrome oxidase and the catalytic role of phospholipid. Biochem Biophys Res Commun 1980;93:1238-46.
33. Goormaghtigh E, Brasseur R, Ruysschaert JM. Adriamycin inactivates cytochrome C oxidasc by exclusion of the enzyme from its cardiolipin essential environment. Biochem Biophys Res Commun 1982;104:314-20.
34. Batelli D, Bellei M, Arrigoni-Martelli E, Mucscatello U, Bobyleva V. Interaction of carnitine with mitochondrial cardiolipin. Biochim Biophys Acta 1992;1117:33-6.
35. Iwamoto Y, Hansen IL, Porter TH. Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxidase by adriamycin and other quinones having antitumor activity. Biochem Biophys Res Commun 1974;58:633-8.
36. Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine: prevention by forms of coenzyme Q of the inhibition by adriamycin of coenzyme Q10-enzymes in mitochondria of the myocardium. Proc Natl Acad Sci 1976;73:4653-6.
37. Harris RN, Doroshow JH. Effect of doxorubicin-enhanced hydrogen peroxide and hydroxyl radical formation on calcium sequestration by cardiac sarcoplasmic reticulum. Biochem Biophys Res Commun 1985;130:739-45.
38. Zorzato F, Salviati G, Facchinetti T, Volpe P. Doxorubicin induces calcium release from terminal cisternae of skeletal muscle. J Biol Chem 1985;260:7349-55.
39. Kim DH, Landry AB, Lee YS, Katz AM. Doxorubicin-induced calcium release from cardiac sarcoplasmic reticulum vesicles. Mol Cell Cardiol 1989;21:433-6.
40. Abramson JJ, Salama G. Sulfhydryl oxidation and Ca2+ release from sarcoplasmic reticulum. Mol Cell Biochem 1988;82:81-4.
41. Lederman HM, Cohen A, Lee JWJ, Freedman MH, Gelfand EW. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1984;64:748-53.
42. Hoffbrand AV, Ganeshaguru K, Hooton JWL, Tattersall MHN. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol 1976;33:517-26.
43. Doroshow JH. Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem Biophys Res Commun 1986; 135:330-5.